{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:31Z","timestamp":1793381071532,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81402353"],"award-info":[{"award-number":["81402353"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.intimp.2022.109235","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T14:17:23Z","timestamp":1665152243000},"page":"109235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Tumor-associated macrophages in lymphoma: From mechanisms to therapy"],"prefix":"10.1016","volume":"112","author":[{"given":"Xingfang","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2022.109235_b0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-022-01561-5","article-title":"Reprogramming the tumor microenvironment by genome editing for precision cancer therapy","volume":"21","author":"Liu","year":"2022","journal-title":"Mol. Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-019-0976-4","article-title":"Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis","volume":"18","author":"Wei","year":"2019","journal-title":"Mol. Cancer."},{"issue":"7","key":"10.1016\/j.intimp.2022.109235_b0025","doi-asserted-by":"crossref","first-page":"1596004","DOI":"10.1080\/2162402X.2019.1596004","article-title":"Interaction of tumor-associated macrophages and cancer chemotherapy","volume":"8","author":"Larionova","year":"2019","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: an accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J. Biomed. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2022.109235_b0035","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta. Pharm. Sin. B."},{"issue":"9","key":"10.1016\/j.intimp.2022.109235_b0040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK's Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer."},{"issue":"11","key":"10.1016\/j.intimp.2022.109235_b0045","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0050","first-page":"34","article-title":"Lymphoma: Diagnosis and Treatment","volume":"101","author":"Lewis","year":"2020","journal-title":"Am. Fam. Physician."},{"issue":"6","key":"10.1016\/j.intimp.2022.109235_b0055","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00262-017-1961-7","article-title":"Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor- associated macrophages leads to immune evasion via secretion of IL-6 and IL-10","volume":"66","author":"Che","year":"2017","journal-title":"Cancer. Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1189\/jlb.0211094","article-title":"The historical milestones in the understanding of leukocyte biology initiated by Elie Metchnikoff","volume":"90","author":"Cavaillon","year":"2011","journal-title":"J. Leukoc. Biol"},{"issue":"6","key":"10.1016\/j.intimp.2022.109235_b0065","first-page":"845","article-title":"The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells","volume":"46","author":"Furth","year":"1972","journal-title":"Bull. World. Health. Organ."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.immuni.2014.06.013","article-title":"Origin and functions of tissue macrophages","volume":"41","author":"Epelman","year":"2014","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.intimp.2022.109235_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2020.01.031","article-title":"Tumor-associated macrophages","volume":"30","author":"Cassetta","year":"2020","journal-title":"Curr. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109235_b0080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1309\/AJCPR92TDDFARISU","article-title":"CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma","volume":"141","author":"Koh","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109235_b0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yexcr.2018.03.009","article-title":"Complement 5a stimulates macrophage polarization and contributes to tumor metastases of colon cancer","volume":"366","author":"Piao","year":"2018","journal-title":"Exp. Cell. Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0090","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3389\/fimmu.2018.01930","article-title":"Chemokine-induced macrophage polarization in inflammatory conditions","volume":"9","author":"Ruytinx","year":"2018","journal-title":"Front. Immunol"},{"issue":"20","key":"10.1016\/j.intimp.2022.109235_b0095","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.3390\/ijms21207619","article-title":"CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2022.109235_b0100","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2022.109235_b0105","doi-asserted-by":"crossref","unstructured":"A. Salmaninejad, S.F. Valilou, A. Soltani, S. Ahmadi, Y.J. Abarghan, R.JRosengren, et al., Tumor-associated macrophages: role in cancer development and therapeutic implications, Cell. Oncol (Dordr). 42 (5) (2019) 591\u2013608.","DOI":"10.1007\/s13402-019-00453-z"},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0110","article-title":"Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy","volume":"161","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.intimp.2022.109235_b0115","first-page":"iv19-iv29","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann. Oncol."},{"issue":"25","key":"10.1016\/j.intimp.2022.109235_b0120","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2022.109235_b0125","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3109\/10428194.2014.963081","article-title":"CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma","volume":"56","author":"Agur","year":"2015","journal-title":"Leuk. Lymphoma."},{"issue":"19","key":"10.1016\/j.intimp.2022.109235_b0130","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1158\/0008-5472.CAN-18-1367","article-title":"Diverse functions of macrophages in different tumor microenvironments","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer. Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12916-016-0711-6","article-title":"Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma","volume":"14","author":"Guo","year":"2016","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s43046-020-00029-1","article-title":"Clinico-pathological significance of immunohistochemically marked tumor-associated macrophage in classic Hodgkin lymphoma","volume":"32","author":"Abd Allah","year":"2020","journal-title":"J. Egypt. Natl. Canc. Inst."},{"issue":"2","key":"10.1016\/j.intimp.2022.109235_b0145","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22984","article-title":"Role of c-MYC in tumor-associated macrophages and cancer progression","volume":"2","author":"Pello","year":"2013","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.intimp.2022.109235_b0150","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2011-02-339911","article-title":"Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology","volume":"119","author":"Pello","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0155","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1038\/s41598-020-66010-z","article-title":"Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome","volume":"10","author":"Werner","year":"2020","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.intimp.2022.109235_b0160","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.7150\/thno.44523","article-title":"Nanotherapy delivery of c-myc inhibitor targets protumor macrophages and preserves antitumor macrophages in breast cancer","volume":"10","author":"Esser","year":"2020","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0165","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer. Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.109235_b0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI. Insight."},{"issue":"13","key":"10.1016\/j.intimp.2022.109235_b0175","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer. Res"},{"issue":"22","key":"10.1016\/j.intimp.2022.109235_b0180","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.intimp.2022.109235_b0185","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.intimp.2022.109235_b0190","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.intimp.2022.109235_b0195","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41375-020-0737-9","article-title":"PD-L1\/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma","volume":"34","author":"Kawashima","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.intimp.2022.109235_b0200","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","article-title":"Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy","volume":"26","author":"Liu","year":"2020","journal-title":"Clin. Cancer. Res."},{"issue":"7655","key":"10.1016\/j.intimp.2022.109235_b0205","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0210","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/1061186X.2018.1440400","article-title":"Development of small-molecule immune checkpoint inhibitors of PD-1\/PD-L1 as a new therapeutic strategy for tumour immunotherapy","volume":"27","author":"Li","year":"2019","journal-title":"J. Drug. Target."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.intimp.2022.109235_b0220","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4\u2013positive T cells that are PD-1\u2013negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.intimp.2022.109235_b0225","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.neo.2019.07.006","article-title":"Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer","volume":"21","author":"Fiegle","year":"2019","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0235","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol"},{"issue":"4","key":"10.1016\/j.intimp.2022.109235_b0240","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/cancers12040877","article-title":"Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma","volume":"12","author":"Karihtala","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2022.109235_b0245","unstructured":"DEC-205\/NY-ESO-1 fusion protein CDX-1401, poly ICLC, and IDO1 inhibitor INCB024360 in treating patients with ovarian, fallopian tube, or primary peritoneal cancer in remission. Available from: www.clinicaltrials.gov\/show\/NCT02166905."},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0250","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/1878-0261.12616","article-title":"High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination","volume":"14","author":"Arlt","year":"2020","journal-title":"Mol. Oncol."},{"issue":"20","key":"10.1016\/j.intimp.2022.109235_b0255","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0260","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12814","article-title":"The prognostic value of tumour-associated macrophages in Non-Hodgkin's lymphoma: A systematic review and meta-analysis","volume":"91","author":"Xu","year":"2020","journal-title":"Scand. J. Immunol."},{"issue":"22","key":"10.1016\/j.intimp.2022.109235_b0265","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.3390\/ijms21228553","article-title":"Novel therapies for relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Harris","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0270","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12885-019-6208-x","article-title":"Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count","volume":"19","author":"Li","year":"2019","journal-title":"BMC. Cancer."},{"issue":"6","key":"10.1016\/j.intimp.2022.109235_b0275","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/ejh.13324","article-title":"Association of CD204 + macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT","volume":"103","author":"Kawajiri","year":"2019","journal-title":"Eur. J. Haematol"},{"issue":"2","key":"10.1016\/j.intimp.2022.109235_b0280","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12841","article-title":"Diffuse large B cell lymphoma-derived extracellular vesicles educate macrophages to promote tumours progression by increasing PGC-1\u03b2","volume":"91","author":"Liu","year":"2020","journal-title":"Scand. J. Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0285","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.2147\/CMAR.S203010","article-title":"NSE from diffuse large B-cell lymphoma cells regulates macrophage polarization","volume":"17","author":"Zhu","year":"2019","journal-title":"Cancer. Manag. Res."},{"issue":"2","key":"10.1016\/j.intimp.2022.109235_b0290","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2012-08-449306","article-title":"A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice","volume":"122","author":"Zonari","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0295","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/imm.12468","article-title":"Physiological roles of miR-155","volume":"145","author":"Mashima","year":"2015","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.intimp.2022.109235_b0300","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/bloodadvances.2018020602","article-title":"PD-L1 and tumor-associated macrophages in de novo DLBCL","volume":"3","author":"McCord","year":"2019","journal-title":"Blood. Adv."},{"issue":"6","key":"10.1016\/j.intimp.2022.109235_b0305","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/his.13857","article-title":"Clinicopathological evaluation of the programmed cell death 1 (PD1)\/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome","volume":"75","author":"Veloza","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.intimp.2022.109235_b0310","unstructured":"A multi-center study of ibrutinib in combination with MEDI4736 in subjects with relapsed or refractory lymphomas. Available from: www.clinicaltrials.gov\/show\/NCT02401048."},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0315","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am. J. Hematol"},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0320","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fonc.2018.00219","article-title":"Cancer immunotherapy and the immune response in follicular lymphoma","volume":"8","author":"Stenner","year":"2018","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109235_b0325","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: A pooled analysis of french and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109235_b0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002197","article-title":"Tan, et al., Histological transformation and progression in follicular lymphoma: A clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS. Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.109235_b0335","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2022.109235_b0340","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3324\/haematol.2017.165415","article-title":"Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the lunenburg lymphoma biomarker consortium","volume":"102","author":"Stevens","year":"2017","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.intimp.2022.109235_b0345","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: A study from the BC cancer agency and the lymphoma study association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin. Cancer. Res."},{"issue":"8","key":"10.1016\/j.intimp.2022.109235_b0350","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s00432-019-02961-9","article-title":"Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial","volume":"145","author":"Budau","year":"2019","journal-title":"J. Cancer. Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0355","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0360","article-title":"Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma","volume":"77","author":"Xie","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109235_b0365","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/cas.13065","article-title":"An IL-27\/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1\/2) on infiltrating macrophages in lymphoma","volume":"107","author":"Horlad","year":"2016","journal-title":"Cancer. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2022.109235_b0370","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-019-0246-0","article-title":"SIRP\u03b1 expression delineates subsets of intratumoral monocyte\/macrophages with different functional and prognostic impact in follicular lymphoma","volume":"9","author":"Chen","year":"2019","journal-title":"Blood. Cancer. J."},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0375","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRP\u03b1-CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends. Immunol."},{"key":"10.1016\/j.intimp.2022.109235_b0380","unstructured":"Study of GS-0189 (Formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed\/refractory non-Hodgkin lymphoma. Available from: www.clinicaltrials.gov\/show\/NCT04502706."},{"issue":"18","key":"10.1016\/j.intimp.2022.109235_b0385","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109235_b0390","first-page":"743","article-title":"The treatment of Burkitt lymphoma in adults","volume":"137","author":"Crombie","year":"2021","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0395","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13027-020-00292-w","article-title":"Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program","volume":"15","author":"Granai","year":"2020","journal-title":"Infect. Agent. Cancer."},{"issue":"7","key":"10.1016\/j.intimp.2022.109235_b0400","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-18-1393","article-title":"Mechanisms of lymphoma clearance induced by high-dose alkylating agents","volume":"9","author":"Lossos","year":"2019","journal-title":"Cancer. Discov."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0405","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3389\/fimmu.2020.01759","article-title":"Potential oncogenic effect of the MERTK-dependent apoptotic-cell clearance pathway in starry-sky B-cell lymphoma","volume":"11","author":"Farnworth-McHugh","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0410","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fonc.2018.00147","article-title":"The role of macrophage\/B-cell interactions in the pathophysiology of B-cell lymphomas","volume":"8","author":"Pham","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2022.109235_b0415","first-page":"7659462","article-title":"CD80 expressed by CD8 + T cells contributes to PD-L1-induced apoptosis of activated CD8 + T cells","author":"Rollins","year":"2017","journal-title":"J Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0420","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12885-018-4266-0","article-title":"Amphotericin B suppresses M2 phenotypes and B7\u2013H1 expression in macrophages to prevent Raji cell proliferation","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC. Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0425","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2022.109235_b0430","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/614619","article-title":"CD47: A cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease","author":"Oldenborg","year":"2013","journal-title":"ISRN. Hematol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109235_b0435","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/cas.13548","article-title":"Anti-human SIRP\u03b1 antibody is a new tool for cancer immunotherapy","volume":"109","author":"Murata","year":"2018","journal-title":"Cancer. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0440","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s40425-019-0772-0","article-title":"Functional characterization of the selective pan-allele anti-SIRP\u03b1 antibody ADU-1805 that blocks the SIRP\u03b1-CD47 innate immune checkpoint","volume":"7","author":"Voets","year":"2019","journal-title":"J. Immunother. Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0445","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3389\/fonc.2020.01226","article-title":"Deregulation of polycomb repressive complex-2 in mantle cell lymphoma confers growth advantage by epigenetic suppression of cdkn2b","volume":"10","author":"Demosthenous","year":"2020","journal-title":"Front. Oncol."},{"issue":"\u20181","key":"10.1016\/j.intimp.2022.109235_b0450","article-title":"High counts of CD68+ and CD163+ macrophages in mantle cell lymphoma are associated with inferior prognosis","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0455","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.17366","article-title":"Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors","volume":"193","author":"Rodrigues","year":"2021","journal-title":"Br. J. Haematol"},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100744","article-title":"Inflammatory infiltrate and angiogenesis in mantle cell lymphoma","volume":"13","author":"Annese","year":"2020","journal-title":"Transl. Oncol."},{"issue":"14","key":"10.1016\/j.intimp.2022.109235_b0465","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/bloodadvances.2020003871","article-title":"Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis","volume":"5","author":"Le","year":"2021","journal-title":"Blood. Adv."},{"issue":"10","key":"10.1016\/j.intimp.2022.109235_b0470","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/s41375-019-0463-3","article-title":"CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages","volume":"33","author":"Papin","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.intimp.2022.109235_b0475","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3390\/cancers12082303","article-title":"Macrophage-mediated antibody dependent effector function in aggressive B-Cell lymphoma treatment is enhanced by ibrutinib via inhibition of JAK2","volume":"12","author":"Barbarino","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2022.109235_b0480","doi-asserted-by":"crossref","unstructured":"S. Decombis, A. Papin, C. Bellanger, C. Sortais, C. Dousset, Y.L. Bris, et al., The IL32\/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition, Haematologica(2022) Online ahead of print.","DOI":"10.3324\/haematol.2021.279800"},{"issue":"7","key":"10.1016\/j.intimp.2022.109235_b0485","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/icb.2017.18","article-title":"MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells","volume":"95","author":"Sanyal","year":"2017","journal-title":"Immunol. Cell. Biol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109235_b0490","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jcyt.2019.04.058","article-title":"T-cell therapies for T-cell lymphoma","volume":"21","author":"Toner","year":"2019","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.intimp.2022.109235_b0495","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"Armitage","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109235_b0500","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.CCR-19-1486","article-title":"Colony-stimulating factor 1 receptor (CSF1R) activates AKT\/mTOR signaling and promotes T-Cell lymphoma viability","volume":"26","author":"Murga-Zamalloa","year":"2020","journal-title":"Clin. Cancer. Res."},{"issue":"9","key":"10.1016\/j.intimp.2022.109235_b0505","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00277-019-03731-w","article-title":"Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T cell lymphoma","volume":"98","author":"Covas Lage","year":"2019","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0510","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1038\/s41598-020-64579-z","article-title":"Predicting worse survival for newly diagnosed T cell lymphoma based on the decreased baseline CD16-\/CD16 + monocyte ratio","volume":"8","author":"Zhang","year":"2020","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.intimp.2022.109235_b0515","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/jid.2014.206","article-title":"Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo","volume":"134","author":"Wu","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109235_b0520","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jid.2019.11.018","article-title":"A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with anti-PD-1 in a murine model of cutaneous T-Cell Lymphoma (CTCL)","volume":"140","author":"Wu","year":"2020","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109235_b0525","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3389\/fonc.2019.00907","article-title":"Bexarotene reduces production of CCL22 from tumor-associated macrophages in cutaneous T-cell lymphoma","volume":"9","author":"Tanita","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2022.109235_b0530","unstructured":"Nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed\/refractory peripheral T Cell lymphoma. Available from: www.clinicaltrials.gov\/show\/NCT03927105."},{"key":"10.1016\/j.intimp.2022.109235_b0535","unstructured":"Safety, tolerability and pharmacokinetics of MRG-106 in patients with mycosis fungoides (MF), CLL, DLBCL or ATLL. Available from: www.clinicaltrials.gov\/show\/NCT02580552."},{"key":"10.1016\/j.intimp.2022.109235_b0540","unstructured":"Study of KW-0761 (Mogamulizumab) in subjects with previously treated peripheral T-cell lymphoma (PTCL). Available from: www.clinicaltrials.gov\/show\/NCT01611142."},{"key":"10.1016\/j.intimp.2022.109235_b0545","unstructured":"Safety, tolerability, pharmacokinetics & pharmacodynamics of toripalimab for patients with recurrent malignant lymphoma. Available from: www.clinicaltrials.gov\/show\/NCT03316144."},{"key":"10.1016\/j.intimp.2022.109235_b0550","unstructured":"MEDI4736 alone and in combination with tremelimumab or AZD9150 in adult subjects with relapsed\/refractory DLBCL (D4190C00023). Available from: www.clinicaltrials.gov\/show\/NCT02549651."},{"key":"10.1016\/j.intimp.2022.109235_b0555","unstructured":"Avelumab in relapsed and refractory peripheral T-cell lymphoma (AVAIL-T). Available from: www.clinicaltrials.gov\/show\/NCT03046953."},{"key":"10.1016\/j.intimp.2022.109235_b0560","unstructured":"Phase I\/Ib study of GWN323 alone and in combination with PDR001 in patients with advanced malignancies and lymphomas. Available from: www.clinicaltrials.gov\/show\/NCT02740270."},{"key":"10.1016\/j.intimp.2022.109235_b0565","unstructured":"Study of tisagenlecleucel in combination with pembrolizumab in r\/r diffuse large B-cell lymphoma patients (PORTIA). Available from: www.clinicaltrials.gov\/show\/NCT03630159."},{"key":"10.1016\/j.intimp.2022.109235_b0570","unstructured":"A trial of pembrolizumab (MK-3475) in participants with blood cancers (MK-3475-013\/KEYNOTE-013). Available from: www.clinicaltrials.gov\/show\/NCT01953692."},{"key":"10.1016\/j.intimp.2022.109235_b0575","unstructured":"Sequential intranodal immunotherapy (SIIT) combined with anti-PD1 (Pembrolizumab) in follicular lymphoma (Lymvac-2). Available from: www.clinicaltrials.gov\/show\/NCT02677155."},{"key":"10.1016\/j.intimp.2022.109235_b0580","unstructured":"PD-1 antibody SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma. Available from: www.clinicaltrials.gov\/show\/NCT03155425."},{"key":"10.1016\/j.intimp.2022.109235_b0585","unstructured":"A study of PD-1\/CTLA-4 bispecific AK104 in relapsed or refractory peripheral T-cell lymphoma. Available from: www.clinicaltrials.gov\/show\/NCT04444141."},{"key":"10.1016\/j.intimp.2022.109235_b0590","unstructured":"Monoclonal antibody therapy in treating patients with lymphoma or colon cancer that has not responded to vaccine therapy. Available from: www.clinicaltrials.gov\/show\/NCT00047164."},{"key":"10.1016\/j.intimp.2022.109235_b0595","unstructured":"Recombinant humanized anti-CD47\/PD-1 bifunctional antibody HX009 in patients with relapsed\/refractory lymphoma. Available from: www.clinicaltrials.gov\/show\/NCT05189093."},{"key":"10.1016\/j.intimp.2022.109235_b0600","unstructured":"A trial of TTI-621 for patients with hematologic malignancies and selected solid tumors. Available from: www.clinicaltrials.gov\/show\/NCT02663518."},{"key":"10.1016\/j.intimp.2022.109235_b0605","unstructured":"Phase 1, dose escalation and dose expansion study of AK117, a CD47 antibody. Available from: www.clinicaltrials.gov\/show\/NCT04728334."},{"key":"10.1016\/j.intimp.2022.109235_b0610","unstructured":"Gentulizumab in patients with advanced solid malignancies and non-Hodgkin lymphoma. Available from: www.clinicaltrials.gov\/show\/NCT05221385."},{"key":"10.1016\/j.intimp.2022.109235_b0615","unstructured":"A study evaluating the safety, tolerability, and initial efficacy of recombinant human anti-cluster differentiation antigen 47 (CD47) monoclonal antibody injection (IBI188) in patients with advanced malignant tumors and lymphomas. Available from: www.clinicaltrials.gov\/show\/NCT03763149."},{"key":"10.1016\/j.intimp.2022.109235_b0620","unstructured":"ALX148, rituximab and lenalidomide for the treatment of indolent and aggressive b-cell non-Hodgkin lymphoma. Available from: www.clinicaltrials.gov\/show\/NCT05025800."},{"key":"10.1016\/j.intimp.2022.109235_b0625","unstructured":"Study of magrolimab and pembrolizumab in relapsed or refractory classic Hodgkin lymphoma. Available from: www.clinicaltrials.gov\/show\/NCT04788043."},{"key":"10.1016\/j.intimp.2022.109235_b0630","unstructured":"A trial of TTI-622 in patients with advanced hematologic malignancies (TTI-622-01). Available from: www.clinicaltrials.gov\/show\/NCT03530683."},{"key":"10.1016\/j.intimp.2022.109235_b0635","unstructured":"A phase II study of oral JAK1\/JAK2 inhibitor INC424 in adult patients with relapsed\/refractory classical Hodgkin's lymphoma (HIJAK). Available from: www.clinicaltrials.gov\/show\/NCT0353."},{"key":"10.1016\/j.intimp.2022.109235_b0640","unstructured":"Pilot study of ruxolitinib in relapsed or refractory Hodgkin lymphoma and primary mediastinal large B-cell lymphoma (JAK2). Available from: www.clinicaltrials.gov\/show\/NCT01965119."},{"key":"10.1016\/j.intimp.2022.109235_b0645","unstructured":"Platform study for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (PRISM Study) (PRISM). Available from: www.clinicaltrials.gov\/show\/NCT03527147."},{"key":"10.1016\/j.intimp.2022.109235_b0650","unstructured":"Study of WP1220 for the treatment of adult subjects with cutaneous T-cell lymphoma (CTCL). Available from: www.clinicaltrials.gov\/show\/NCT04702503."},{"key":"10.1016\/j.intimp.2022.109235_b0655","unstructured":"Phase 1\/2, open-label, dose-escalation study of IONIS-STAT3Rx, administered to patients with advanced cancers. Available from: www.clinicaltrials.gov\/show\/NCT01563302."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:51:17Z","timestamp":1761587477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922007196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":131,"alternative-id":["S1567576922007196"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109235","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-associated macrophages in lymphoma: From mechanisms to therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109235"}}